Stephen Potter, MD
Ophthalmology · Aiken, SCNPI 1982043626
Payments from drug & device makers
Across 167 payments — averaging $27.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$743
- AbbVie$422
- Oyster Point Pharma, Inc.$383
- Bausch & Lomb, A Division Of Bausch Health US, LLC$376
- Sight Sciences, Inc.$367
- Mallinckrodt Hospital Products Inc.$355
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,541100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 26 | $743 |
| AbbVie(2 entities) | 15 | $422 |
| Oyster Point Pharma, Inc. | 15 | $383 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $376 |
| Sight Sciences, Inc. | 10 | $367 |
| Mallinckrodt Hospital Products Inc. | 17 | $355 |
| NEW World Medical,inc. | 3 | $328 |
| Amgen(2 entities) | 14 | $272 |
| Sun Pharmaceutical Industries Inc. | 10 | $260 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $236 |
| Alcon | 9 | $180 |
| Novartis | 10 | $146 |
| Tarsus Pharmaceuticals, Inc. | 3 | $78 |
| Harrow Eye, LLC | 2 | $75 |
| Rayner Intraocular Lenses Limited | 3 | $61 |
| Aerie Pharmaceuticals, Inc. | 3 | $49 |
| Glaukos Corporation | 2 | $43 |
| Thea Pharma Inc. | 2 | $40 |
| Rxsight Inc | 2 | $40 |
| Biotissue Holdings Inc. | 3 | $29 |
| Kala Pharmaceuticals, Inc. | 2 | $28 |
| Dompe US, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$485
- Kahook Dual Blade$262
- Ahmed Glaucoma Valve$262
- OMNI(R) SURGICAL SYSTEM (US)$237
- TYRVAYA$150
- Clearpath$138
- Streamline$138
- Via360$138
- SION SURGICAL INSTRUMENT$129
- CEQUA$125
- LUMIGAN$125
- COMBIGAN$125
- Streamline Surgical System$124
- Tecnis IOL$102
- Tecnis Multifocal Family of 1-piece IOLS$101
How this compares
$4,541 in reported general payments places this provider in the 65th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 56 | $91,990 |
| RestasisCyclosporine | 59 | $71,470 |
| LumiganBimatoprost | 130 | $65,469 |
| RocklatanNetarsudil Mesylat/Latanoprost | 34 | $16,652 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $10,928 |
| Prednisolone Acetate | 219 | $8,211 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 55 | $7,813 |
| TyrvayaVarenicline Tartrate | 13 | $7,779 |
| Cyclosporine | 20 | $7,542 |
| Latanoprost | 559 | $6,280 |
| Alphagan PBrimonidine Tartrate | 17 | $5,062 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 94 | $4,117 |
| Travoprost | 22 | $3,444 |
| Brimonidine Tartrate | 154 | $3,128 |
| Timolol Maleate | 147 | $2,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $422 | $152,929232 claims |
| Bausch & Lomb Americas Inc.Xiidra | $743 | $91,99056 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $49 | $16,65234 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $383 | $7,77913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Aiken
- Anthony GreerAiken$37K
- Kishan GovindAiken$11K
- John WellsWest Columbia$7.1M
- William ClarkWest Columbia$6.2M
- Daniel AlfaroCharleston$4.6M
- Kerry SolomonMt Pleasant$4.6M
- Eric JablonCharleston$1.2M
- George WaringMt Pleasant$1M
- John KerrisonCharleston$975K
- Karolinne RochaCharleston$799K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.